|
**Overview**: Acute Kidney Injury Panel**Introduction**: The Acute Kidney Injury Panel is a diagnostic tool designed to assess acute kidney injury using serum samples. In India, AKI poses a major public health challenge, with over 85% of the global burden in low- and middle-income countries like India. Community-acquired AKI (CA-AKI) dominates, linked to sepsis (34.7%), tropical fevers (9.8% including dengue/malaria), dehydration, and volume depletion, especially in rural and low-socioeconomic populations. Hospital-acquired AKI (HA-AKI) arises from trauma, cardiac issues, and ICU exposures. Incidence reaches 30-60% in ICUs, with high morbidity from delayed presentation, underdiagnosis, and limited dialysis access in resource-limited areas. Patients exhibit oliguria, edema, fatigue, and complications like progression to chronic kidney disease or renal replacement therapy need. Mortality ranges from 10.8% (index admission in ISN-AKI registry) to 42-52% in critically ill cohorts, higher in sepsis cases (up to 43%). Aligned with KDIGO guidelines (adapted locally by Indian Society of Nephrology), the test uses spectrophotometry for detailed analysis over 1-2 days with high sensitivity/specificity, aiding early detection in at-risk groups such as diabetics (19%), hypertensives (21%), and tropical infection patients. This biochemistry diagnostic targets suspected AKI in medical/surgical/obstetrical settings, addressing challenges in diverse Indian populations to guide fluid management, sepsis control, and prevention of long-term issues like dialysis dependency (9.4% at discharge). With elevated morbidity from underdiagnosis in rural areas and seasonal tropical fevers, the test supports initiatives for timely intervention and reduced healthcare burden. Its serum-based approach ensures reliable assessment even in varied lab settings across states.**Other Names**: AKI Pnl.**FDA Status**: FDA approved, CLIA certified for clinical chemistry, compliant with 2025 standards; aligns with Indian regulatory frameworks for diagnostics.**Historical Milestone**: Evolved in early 2000s with novel biomarkers (NGAL, KIM-1) for early detection; in India, gained prominence post-KDIGO adoption and multicenter registries highlighting CA-AKI burden.**Purpose**: The test screens for 9 parameters including creatinine to guide AKI assessment, evaluate kidney function markers (electrolytes, novel biomarkers), inform etiology (sepsis vs. tropical vs. pre-renal), and support treatment/prevention strategies in high-risk Indian scenarios like tropical infections and critical care.**Test Parameters**: 1. Creatinine, 2. Urea, 3. Sodium, 4. Potassium, 5. Chloride, 6. Bicarbonate, 7. Cystatin C, 8. NGAL, 9. KIM-1.**Pretest Condition**: Fasting 10-12 hours recommended; patients should report oliguria, edema, fatigue, dehydration, recent fever/infection (dengue/malaria common in India), or critical illness.**Specimen**: 3 mL serum in 1 SST, transported promptly to maintain viability, crucial in India's varied transport conditions.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable performance amid potential delays in resource-limited settings.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before processing, though immediate testing preferred in high-burden areas.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting in referral labs, though freezing may affect some biomarkers.**Medical History**: Patients should provide details on oliguria, edema, fatigue, prior kidney issues, dehydration, tropical fevers, sepsis, medications (nephrotoxic drugs common), or family history of renal disease; low SES increases risk.**Consent**: Written informed consent required, detailing purpose, risks of untreated AKI (progression to CKD/dialysis/death, high in India ~10-50%), benefits of early detection (reduced mortality/dialysis dependency), and minimal venipuncture discomfort.**Procedural Considerations**: Sample processing uses spectrophotometry by trained personnel ensuring sterile technique, avoiding hemolysis (common issue in Indian labs), interpreting results in 1-2 days with controls. Labs maintain controlled environments, quality assurance, and kit storage per specs for reliability in diverse settings.**Factors Affecting Result Accuracy**: Delays beyond stability, improper storage, hemolysis, dehydration/hypotension (prevalent in India), diuretic use, or tropical infections can affect results. Clinical correlation/additional testing recommended.**Clinical Significance**: Abnormal results indicate AKI, necessitating specialist input or further tests. Normal may need follow-up if symptoms persist amid high Indian burden.**Specialist Consultation**: General practitioners/nephrologists for management, treatment (fluids/dialysis), coordination with programs in high-prevalence areas.**Additional Supporting Tests**: Urine output, full electrolytes, tropical fever serology, renal ultrasound for confirmation.**Test Limitations**: May mislead in pre-renal vs. intrinsic causes/early stages; requires comprehensive approach with clinical correlation, especially in tropical/sepsis contexts.**References**: KDIGO Guidelines (adapted India), ISN-AKI Registry India 2024, Indian Journal of Nephrology 2023-2025, Tropical fever studies 2023. |
